Healthcare Industry News: schizophrenia
News Release - June 1, 2006
Alpharma Names Dean J. Mitchell President and CEOFORT LEE, N.J., June 1 (HSMN NewsFeed) -- Alpharma Inc. (NYSE: ALO ), a leading global specialty pharmaceutical company, announced today that the board of directors has named Dean J. Mitchell President and CEO, effective July 1. Mr. Mitchell will succeed Ingrid Wiik, who previously announced she planned to retire as CEO once a successor was named.
Mr. Mitchell, 50, has nearly three decades of senior management experience working at global pharmaceutical companies including Bristol-Myers Squibb Company and GlaxoSmithKline. In addition to overseeing various multi-billion dollar businesses, Mr. Mitchell also worked in strategic planning and product development and commercialization. He was most recently President and CEO of Guilford Pharmaceuticals, where he directed a comprehensive overhaul of the biotechnology company's strategy leading to its acquisition by MGI Pharma Inc.
Alpharma plans to elect Mr. Mitchell to its board of directors on July 1; Ms. Wiik will retire as CEO on June 30, but will remain a director.
"Dean's extensive industry experience, leadership abilities, and proven track record of running pharmaceutical businesses make him ideally suited to oversee Alpharma's growth and expansion," said Peter G. Tombros, chairman of Alpharma's board of directors. "Dean has already demonstrated that he can successfully transition from working at major pharmaceutical companies to one with a more specialized and entrepreneurial focus, and we are excited that he has agreed to commit his expertise to Alpharma."
Mr. Mitchell commented: "Alpharma in the past 18 months has completed an impressive restructuring of its businesses, operations, and balance sheet, and I'm delighted to have an opportunity to lead the company as it enters a growth stage of development. I look forward to working with Alpharma's exceptional senior management team and to helping build a strong, market-driven Specialty Pharma company for the benefit of its customers, shareholders, and employees."
Prior to joining Guilford, Mr. Mitchell held a broad range of operations and strategic positions at Bristol-Myers Squibb, lastly being responsible for developing corporate strategy. Previously, he was president of its North America Primary Care and International Pharmaceuticals businesses, where he oversaw the launch of Abilify for the treatment of schizophrenia and bipolar disorder, one of the top 10 drug launches in the U.S. Mitchell also served on various Bristol-Myers Squibb senior management and governance committees, including its Corporate Executive Committee.
Before joining Bristol-Myers Squibb, Mr. Mitchell spent 14 years at GlaxoSmithKline and its predecessor companies in the U.S. and Canada where he held various general management, product strategy and business development positions. His last role combined the global clinical development and global marketing organizations into a group which shaped products for effective commercialization.
Born in the U.K., Mr. Mitchell earned his MBA from City University Business School and his Bachelor of Science degree from Coventry University. He is previous Vice Chairman of the National Pharmaceutical Council, and a member of the board of directors of ISTA Pharmaceuticals and MGI Pharma.
Alpharma press releases are also available at our website: http://www.alpharma.com.
Alpharma Inc. (NYSE: ALO ) is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 60 countries. Alpharma has a growing branded franchise in the chronic pain market with its morphine-based extended release KADIAN® product. In addition, Alpharma is among the world's leading producers of several specialty pharmaceutical-grade bulk antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry and livestock.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.